Topic: mergers and acquisitions
JLABS lands first ex-North America site in Shanghai, Sanofi's Dengvaxia situation quickly worsens in the Philippines, Astellas buys DMD biotech.
Cardinal Health has agreed to sell its China business to Shanghai Pharma for $557 million in cash.
CDMO Almac has added to its analytical services with the acquisition of a privately held drug testing and analytical services company.
Aviragen and Vaxart merged into one company aimed at developing oral vaccines against flu, norovirus and RSV.
Novartis' $3.9B deal for Advanced Accelerator Applications comes with a blockbuster-to-be, Lutathera, that could follow in Sandostatin's footsteps.
AZ and Chi-Med scores early data for savolitinib combos in lung cancer, WuXi AppTec buys a U.S. CRO, FDA clears Sun's Dadra plant.
Amgen inked a biosim deal with Simcere, Gilead won a Chinese nod for Sovaldi, and Shanghai Pharma is in talks to buy part of Alvogen.
Not all Big Pharma's businesses in emerging markets are doing so well, Fosun is buying a smaller stake in Gland, Taiho and Arcus ink cancer option deal.
UDG Healthcare recently picked up its third U.S. healthcare agency in three months. The healthcare services company bought MicroMass $75.8 million.